Introduction
The antifolate methotrexate (MTX), is used to treat a range of malignancies including childhood acute lymphoblastic leukemia. Resistance to this drug may be attributable to a number of mechanisms including increased levels of the target enzyme dihydrofolate reductase (DHFR) due to amplification or increased expression of the DHFR gene; reduced binding of MTX to DHFR due to modification of the protein; or reduced intracellular accumulation of drug due to altered permeability of drug across the cell membrane or alteration in the rate or extent of polyglutamylation. While changes in DHFR structure and expression have been definitively characterised, less clear information is available regarding membrane alterations mediating reduced MTX transport into the cell.
We have previously described a series of three human leukemic sublines (CEM/MTX RI -R3) which were developed by progressive exposure of human lymphoblastoid CCRF-CEM cells to concentrations of MTX up to 5 χ ΙΟ" 4 M (1 CEM MTX R4 and R5 sublines were derived from CEM MTX R3 (1) by selection with 1 mM and 2 mM MTX, respectively. Cytotoxicity determinations, determination of DHFR gene copy number and studies of drug accumulation were performed as described previously (1, 2) and expression of the human folate binding protein (FBP) gene was determined using the polymerase chain reaction (PCR) (3). Antiserum was prepared in rabbits to the membrane transporter (GP-MTX) isolated from transport-upregulated K562 human erythroleukemia cells by Ricinus communis agglutinin I lectin-agarose chromatography and preparative electrophoresis (4). Plasma membrane isolations and SDS gradient (4 -10%) gel electrophoresis of membrane proteins were carried out as described (5) . Detection of immunoreactive proteins on Western blots was with 125 I-Protein A. (Table 1) revealed that all 5 sublines were highly resistant to MTX and that their level of resistance increased across the series. The most resistant subline, CEM/MTX R5, was in excess of 500,000 times more resistant to MTX than the drugsensitive parent line. Increasing resistance correlated with progressive amplification of the DHFR gene. However despite DHFR amplification, the CEM/ MTX RI -R5 cells were relatively sensitive to the lipophilic antifolate, TMQ.
Results

ID50 determination
By comparison with CCRF-CEM cells, all 5 MTXresistant sublines displayed markedly decreased intracellular accumulation of MTX at external drug concentrations of both 2.5 and 200 μΜ, no significant differences between the various sublines being apparent at either concentration. In order to characterise changes contributing to reduced MTX accumulation, plasma membranes were prepared from both parental and MTX resistant CCRF-CEM sublines. Membrane proteins were solubilized and analysed on Western blots with antiserum to the isolated membrane transporter. Compared to the wild type cells (approx. M r = 130 kDa), each of the transport-impaired CCRF-CEM sublines expressed a structurally altered carrier isoform (M r = 106-108 kDa; Table 1 ). Using reverse transcription-PCR, expression of the gene for FBP, an additional mode of folate and MTX uptake in mammalian cells, was detected in KB cells but not in either the parental or MTX-resistant CCRF-CEM sublines.
Discussion and Conclusion
The data indicate that at least two well characterised mechanisms of MTX resistance are operating in the CEM/MTX RI -R5 cells. Resistance in these sublines appears to be mediated both by amplification and consequent overexpression of the target gene DHFR and by markedly reduced accumulation of MTX. The relative contribution of each to these mechanisms to the resistance phenotype exhibited by the CEM/MTX RI -R5 series is indicated by their response to TMQ, a lipophilic antifolate which enters cells by a process distinct from specific MTX transport routes. TMQ is a potent inhibitor of DHFR and cells resistant to MTX solely by virtue of DHFR amplification are also known to be resistant to TMQ. However, cell populations resistant to MTX solely through a transport defect, are sensitive to TMQ. Since the RI -R5 series of sublines display only minimal resistance to this drug despite their DHFR amplification (Table 1) , the data therefore suggest that deficient MTX transport into the cells is the major factor contributing to their MTX resistance.
There are two major pathways for entry of MTX into mammalian cells, both of which appear to have a physiological role in folate transport. The 'classic' high affinity/low capacity reduced folate carrier, has high affinity for MTX but low affinity for folic acid. The other class of proteins, membrane FBPs, have high affinity for folic acid but lower affinity for MTX. Since FBP expression could not be detected by PCR in the parent or MTX resistant cells, it is unlikely that FBP plays a significant role in MTX transport in these cells. However, an immunoreactive membrane protein, apparently identical to the classical transporter found in human tumor cells was detected in all of the CCRF-CEM sublines. For the CEM/MTX RI -R5 cells, impaired transport correlated with significantly altered electrophoretic migration of this immunoreactive protein. Combined with the results indicating reduced MTX accumulation, these data strongly suggest that alterations in this protein may be important to mediating MTX resistance in leukemia cells.
